Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Hydralazine

4

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

1
Last update : 21/08/2012
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Diffuse Alveolar Hemorrhage Linked to Hydralazine.
Journal of Brown hospital medicine 2024;3;32-35 2024
Diagnostic dilemma: drug-induced vasculitis versus systemic vasculitis.
BMJ case reports 2023 Jul 10;16; 2023 Jul 10
The Utility of Bronchoscopy in Hydralazine-Induced ANCA-Associated Vasculitis.
Case reports in pulmonology 2023;2023;1461011 2023
Hydralazine-Induced Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: A Case Report and Literature Review.
Cureus 2022 Apr;14;e24132 2022 Apr
Hydralazine-Induced ANCA Associated Vasculitis (AAV) Presenting with Pulmonary-Renal Syndrome (PRS): A Case Report with Literature Review.
Current cardiology reviews 2021;17;182-187 2021
Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary-renal syndrome: a case report.
Journal of medical case reports 2020 Apr 15;14;47 2020 Apr 15
Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis.
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2019;30;226-230 2019
Hydralazine-induced pulmonary-renal syndrome: a case report.
American journal of therapeutics 2012 Jul;19;e136-8 2012 Jul

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies